
Leerink raised the firm’s price target on Zimmer Biomet (ZBH) to $112 from $110 and keeps a Market Perform rating on the shares. The firm has growing conviction that MedTech
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ZBH | Zimmer Biomet Holdings | 101.67 | 14.58 | 16.74% |
| Name | Price | % Change | |
|---|---|---|---|
| $101.67 | +16.74% |

Leerink raised the firm’s price target on Zimmer Biomet (ZBH) to $112 from $110 and keeps a Market Perform rating on the shares. The firm has growing conviction that MedTech

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

Wells Fargo upgraded Zimmer Biomet (ZBH) to Overweight from Equal Weight with a price target of $123, up from $113. The firm says Monogram should lift Zimmer’s knee and worldwide

BMO Capital lowered the firm’s price target on Zimmer Biomet (ZBH) to $101 from $102 and keeps a Market Perform rating on the shares. The firm is adjusting its model

Stifel analyst Rick Wise raised the firm’s price target on Zimmer Biomet (ZBH) to $140 from $125 and keeps a Buy rating on the shares. Published first on TheFly –

Analyst Travis Steed of Bank of America Securities maintained a Hold rating on Zimmer Biomet Holdings, boosting the price target to $120.00. Travis Steed gave his rating based on several

Zimmer Biomet Holdings ( ($ZBH) ) has provided an update. On November 5, 2026, Zimmer Biomet Holdings entered underwriting agreements for €500.0 million of 4.375% notes due 2033 and $500.0

Barclays raised the firm’s price target on Zimmer Biomet (ZBH) to $115 from $100 and keeps an Equal Weight rating on the shares. The company showed encouraging progress excluding knees

Truist analyst Richard Newitter raised the firm’s price target on Zimmer Biomet (ZBH) to $114 from $106 and keeps a Hold rating on the shares. Q3 saw another quarter of

RBC Capital raised the firm’s price target on Zimmer Biomet (ZBH) to $125 from $110 and keeps an Outperform rating on the shares. The firm cites the company’s Q3 earnings
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Assigned | Nov 19, 2026 | ||||
| buy | Upgraded | Nov 17, 2026 | ||||
| hold | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 16, 2026 | ||||
| hold | Reiterated | Nov 15, 2026 | ||||
| hold | Reiterated | Nov 9, 2026 | ||||
| hold | Reiterated | Nov 9, 2026 | ||||
| hold | Reiterated | Nov 5, 2026 | ||||
| hold | Reiterated | Nov 5, 2026 | ||||
| hold | Reiterated | Nov 5, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 11, 2027TBA | $19.32B | $2.49 | $2.29B | -1.26 | 26.02 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.